Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus

References

• Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 2003;47:548–53.10.1128/AAC.47.2.548-553.2003
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Namdar R, Singleton MD, Nix DE. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest. 1999;115:12–8.10.1378/chest.115.1.12
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet. 2003;42:1129–40.10.2165/00003088-200342130-00004
   PubMed Web of Science ®Google Scholar
• Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983;5(Suppl 3):428–32.10.1093/clinids/5.Supplement_3.S428
   PubMedGoogle Scholar
• Strukova EN, Portnoy YA, Zinner SH, Firsov AA. Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentrations. J Antimicrob Chemother. 2016;71:678–84.10.1093/jac/dkv387
   PubMed Web of Science ®Google Scholar
• Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother. 1985;15(Suppl A):131–7.10.1093/jac/15.suppl_A.131
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-eighth edition, Document M-07-08. Wayne, PA: CLSI; 2009.
   Google Scholar
• Firsov AA, Saverino D, Ruble M, Gilbert D, Manzano B, Medeiros AA, et al. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother. 1996;40:734–8.
   PubMed Web of Science ®Google Scholar
• Egle H, Trittler R, Kummerer K, Lemmen SW. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther. 2005;77:451–3.10.1016/j.clpt.2005.01.020
   PubMed Web of Science ®Google Scholar
• Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy. 2007;27:476–9.10.1592/phco.27.3.476
   PubMed Web of Science ®Google Scholar
• Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51:229–36.10.1177/0091270010366445
   PubMed Web of Science ®Google Scholar
• Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, Climent C, Brunet M, Cuesta M, et al. Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis. 2012;44:548–50.10.3109/00365548.2012.663931
   PubMed Web of Science ®Google Scholar
• Gervasoni C, Simonetti FR, Resnati C, Charbe N, Clementi E, Cattaneo D. Prolonged inductive effect of rifampicin on linezolid exposure. Eur J Clin Pharmacol. 2015;71:643–4.10.1007/s00228-015-1833-z
   PubMed Web of Science ®Google Scholar
• Blassmann U, Roehr AC, Frey OR, Koeberer A, Briegel J, Huge V, et al. Decreased linezolid serum concentrations in three critically ill patients: clinical case studies of a potential drug interaction between linezolid and rifampicin. Pharmacology. 2016;98:51–5.10.1159/000445194
   PubMed Web of Science ®Google Scholar
• Smirnova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, et al. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother. 2011;23:140–4.10.1179/joc.2011.23.3.140
   PubMed Web of Science ®Google Scholar
• Strukova EN, Smirnova MV, Vostrov SN, Lubenko IY, Firsov AA, Zinner SH, et al. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Int J Antimicrob Agents. 2009;33:251–4.10.1016/j.ijantimicag.2008.09.006
   PubMed Web of Science ®Google Scholar
• Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estévez R, Cantón E, Gobernado M. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimiote.r 2006;19:252–7.
   PubMedGoogle Scholar
• Sweeney MT, Zurenko GE. In vitro activities of linezolid combined with other antimicrobial agents against staphylococci, enterococci, pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother. 2003;47:1902–6.10.1128/AAC.47.6.1902-1906.2003
   PubMed Web of Science ®Google Scholar
• Den Hollander JG, Mouton JW, Verbrugh HA. Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics. Antimicrob Agents Chemother. 1998;42:744–8.
   PubMed Web of Science ®Google Scholar
• Mouton JW, van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamic parameters to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother. 1999;43:2473–8.
   PubMed Web of Science ®Google Scholar
• Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Lorian V., editor. Antibiotics in laboratory medicine, 5th Edition. Lippincott Williams & Wilkins; Philadelphia, 2005, Chapter 9. p. 373.
   Google Scholar
• Foweraker JE, Laughton CR, Brown DF, Bilton D. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis. Antimicrob Agents Chemother. 2009;53:4809–15.10.1128/AAC.00269-09
   PubMed Web of Science ®Google Scholar
• Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, et al. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:5251–6.10.1128/AAC.00226-10
   PubMed Web of Science ®Google Scholar
• Grohs P, Kitzis MD, Gutmann L. In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against staphylococcus aureus. Antimicrob Agents Chemothe.r 2003;47:418–20.10.1128/AAC.47.1.418-420.2003
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Caillon J, Le Mabecque V, Miegeville AF, Donnio PY, Bugnon D, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother. 2003;51:857–64.10.1093/jac/dkg160
   PubMed Web of Science ®Google Scholar
• Murillo O, Domenech A, Euba G, Verdaguer R, Tubau F, Cabo J, et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect. 2008;57:229–35.10.1016/j.jinf.2008.07.003
   PubMed Web of Science ®Google Scholar
• Cabellos C, Garrigós C, Taberner F, Force E, Pachón-Ibañez ME. Experimental study of the efficacy of linezolid alone and in combinations against experimental meningitis due to Staphylococcus aureus strains with decreased susceptibility to beta-lactams and glycopeptides. J Infect Chemother. 2014;20:563–8.10.1016/j.jiac.2014.05.008
   PubMed Web of Science ®Google Scholar
• Firsov AA, Golikova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, et al. Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin. J Chemother. Forthcoming 2016. doi:10.1080/1120009X.2016.1245174.
   Web of Science ®Google Scholar